Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia

J. Bertrand, H. Dostálová, V. Kryštof, R. Jorda, T. Delgado, A. Castro-Alvarez, J. Mella, D. Cabezas, M. Faúndez, C. Espinosa-Bustos, CO. Salas

. 2022 ; 14 (6) : . [pub] 20220617

Language English Country Switzerland

Document type Journal Article

Grant support
21-06553S Czech Science Foundation
IGA_PrF_2022_007 Palacký University, Olomouc
ENOCH, No. CZ.02.1.01/0.0/0.0/16_019/0000868 European Regional Development Fund
No21180975. Conicyt, Chile

We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structures of well-known kinase inhibitors and our previously developed purine derivatives. The synthesis of these purines was simple and used a microwave reactor for the final step. Kinase assays showed three inhibitors with high selectivity for each protein that were identified: 4f (IC50 = 70 nM for Bcr-Abl), 5j (IC50 = 0.41 μM for BTK) and 5b (IC50 = 0.38 μM for FLT-ITD). The 3D-QSAR analysis and molecular docking studies suggested that two fragments are potent and selective inhibitors of these three kinases: a substitution at the 6-phenylamino ring and the length and volume of the alkyl group at N-9. The N-7 and the N-methyl-piperazine moiety linked to the aminophenyl ring at C-2 are also requirements for obtaining the activity. Furthermore, most of these purine derivatives were shown to have a significant inhibitory effect in vitro on the proliferation of leukaemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos) at low concentrations. Finally, we show that the selected purines (4i, 5b and 5j) inhibit the downstream signalling of the respective kinases in cell models. Thus, this study provides new evidence regarding how certain chemical modifications of purine ring substituents provide novel inhibitors of target kinases as potential anti-leukaemia drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22016970
003      
CZ-PrNML
005      
20220720100044.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14061294 $2 doi
035    __
$a (PubMed)35745866
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bertrand, Jeanluc $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
245    10
$a Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia / $c J. Bertrand, H. Dostálová, V. Kryštof, R. Jorda, T. Delgado, A. Castro-Alvarez, J. Mella, D. Cabezas, M. Faúndez, C. Espinosa-Bustos, CO. Salas
520    9_
$a We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structures of well-known kinase inhibitors and our previously developed purine derivatives. The synthesis of these purines was simple and used a microwave reactor for the final step. Kinase assays showed three inhibitors with high selectivity for each protein that were identified: 4f (IC50 = 70 nM for Bcr-Abl), 5j (IC50 = 0.41 μM for BTK) and 5b (IC50 = 0.38 μM for FLT-ITD). The 3D-QSAR analysis and molecular docking studies suggested that two fragments are potent and selective inhibitors of these three kinases: a substitution at the 6-phenylamino ring and the length and volume of the alkyl group at N-9. The N-7 and the N-methyl-piperazine moiety linked to the aminophenyl ring at C-2 are also requirements for obtaining the activity. Furthermore, most of these purine derivatives were shown to have a significant inhibitory effect in vitro on the proliferation of leukaemia and lymphoma cells (HL60, MV4-11, CEM, K562 and Ramos) at low concentrations. Finally, we show that the selected purines (4i, 5b and 5j) inhibit the downstream signalling of the respective kinases in cell models. Thus, this study provides new evidence regarding how certain chemical modifications of purine ring substituents provide novel inhibitors of target kinases as potential anti-leukaemia drugs.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dostálová, Hana $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000261236450
700    1_
$a Kryštof, Vladimír $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000158382118 $7 xx0097406
700    1_
$a Jorda, Radek $u Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000249057126
700    1_
$a Delgado, Thalía $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
700    1_
$a Castro-Alvarez, Alejandro $u Departamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Manuel Montt 112, Temuco 4780000, Chile $1 https://orcid.org/0000000183608027
700    1_
$a Mella, Jaime $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Avenida Gran Bretaña 1111, Valparaíso 2360102, Chile $u Facultad de Farmacia, Centro de Investigación Farmacopea Chilena, Universidad de Valparaíso, Avenida Gran Bretaña 1093, Valparaíso 2360102, Chile $1 https://orcid.org/0000000224348461
700    1_
$a Cabezas, David $u Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Avenida Gran Bretaña 1111, Valparaíso 2360102, Chile
700    1_
$a Faúndez, Mario $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile
700    1_
$a Espinosa-Bustos, Christian $u Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile $1 https://orcid.org/0000000160388439
700    1_
$a Salas, Cristian O $u Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Avenida Vicuña Mackenna 4860, Santiago 7820436, Chile $1 https://orcid.org/0000000176202459
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 6 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35745866 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100040 $b ABA008
999    __
$a ind $b bmc $g 1816391 $s 1168212
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 6 $e 20220617 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 21-06553S $p Czech Science Foundation
GRA    __
$a IGA_PrF_2022_007 $p Palacký University, Olomouc
GRA    __
$a ENOCH, No. CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
GRA    __
$a No21180975. $p Conicyt, Chile
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...